These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32467343)

  • 1. Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.
    Torrejon DY; Abril-Rodriguez G; Champhekar AS; Tsoi J; Campbell KM; Kalbasi A; Parisi G; Zaretsky JM; Garcia-Diaz A; Puig-Saus C; Cheung-Lau G; Wohlwender T; Krystofinski P; Vega-Crespo A; Lee CM; Mascaro P; Grasso CS; Berent-Maoz B; Comin-Anduix B; Hu-Lieskovan S; Ribas A
    Cancer Discov; 2020 Aug; 10(8):1140-1157. PubMed ID: 32467343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
    Zaretsky JM; Garcia-Diaz A; Shin DS; Escuin-Ordinas H; Hugo W; Hu-Lieskovan S; Torrejon DY; Abril-Rodriguez G; Sandoval S; Barthly L; Saco J; Homet Moreno B; Mezzadra R; Chmielowski B; Ruchalski K; Shintaku IP; Sanchez PJ; Puig-Saus C; Cherry G; Seja E; Kong X; Pang J; Berent-Maoz B; Comin-Anduix B; Graeber TG; Tumeh PC; Schumacher TN; Lo RS; Ribas A
    N Engl J Med; 2016 Sep; 375(9):819-29. PubMed ID: 27433843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
    Shin DS; Zaretsky JM; Escuin-Ordinas H; Garcia-Diaz A; Hu-Lieskovan S; Kalbasi A; Grasso CS; Hugo W; Sandoval S; Torrejon DY; Palaskas N; Rodriguez GA; Parisi G; Azhdam A; Chmielowski B; Cherry G; Seja E; Berent-Maoz B; Shintaku IP; Le DT; Pardoll DM; Diaz LA; Tumeh PC; Graeber TG; Lo RS; Comin-Anduix B; Ribas A
    Cancer Discov; 2017 Feb; 7(2):188-201. PubMed ID: 27903500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy.
    Zhang C; Li D; Xiao B; Zhou C; Jiang W; Tang J; Li Y; Zhang R; Han K; Hou Z; Zhang L; Sui Q; Liao L; Pan Z; Zhang X; Ding P
    J Immunother; 2022 May; 45(4):187-193. PubMed ID: 35343934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
    Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
    Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
    Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to PD-1 blockade in melanoma.
    Burki TK
    Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
    Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
    Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.
    Budczies J; Bockmayr M; Klauschen F; Endris V; Fröhling S; Schirmacher P; Denkert C; Stenzinger A
    Genes Chromosomes Cancer; 2017 Aug; 56(8):651-659. PubMed ID: 28466543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor Immune Responses in B2M-Deficient Cancers.
    Torrejon DY; Galvez M; Abril-Rodriguez G; Campbell KM; Medina E; Vega-Crespo A; Kalbasi A; Comin-Anduix B; Ribas A
    Cancer Immunol Res; 2023 Dec; 11(12):1642-1655. PubMed ID: 37801341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
    Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
    Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
    Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8
    Rolig AS; Rose DC; McGee GH; Rubas W; Kivimäe S; Redmond WL
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35444059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1
    Verma V; Shrimali RK; Ahmad S; Dai W; Wang H; Lu S; Nandre R; Gaur P; Lopez J; Sade-Feldman M; Yizhak K; Bjorgaard SL; Flaherty KT; Wargo JA; Boland GM; Sullivan RJ; Getz G; Hammond SA; Tan M; Qi J; Wong P; Merghoub T; Wolchok J; Hacohen N; Janik JE; Mkrtichyan M; Gupta S; Khleif SN
    Nat Immunol; 2019 Sep; 20(9):1231-1243. PubMed ID: 31358999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
    Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of JAK1 Drives Innate Immune Deficiency.
    Witalisz-Siepracka A; Klein K; Prinz D; Leidenfrost N; Schabbauer G; Dohnal A; Sexl V
    Front Immunol; 2018; 9():3108. PubMed ID: 30671064
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.